Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure.

Abstract

Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.

• Authors: Dean M Robinson, Monique P Curran, Katherine A Lyseng-Williamson
• Journal: Drugs (Drugs) Vol. 67 Issue 9 Pg. 1359-78 ( 2007) ISSN: 0012-6667 [Print] New Zealand
• PMID: 17547476 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Imidazolidines
• imidapril

Topics

• Angiotensin-Converting Enzyme Inhibitors (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Diabetes Mellitus, Type 1 (complications)
• Diabetic Nephropathies (drug therapy, etiology)
• Heart Failure (drug therapy)
• Humans
• Hypertension (drug therapy)
• Imidazolidines (adverse effects, chemistry, therapeutic use)
• Molecular Structure
• Treatment Outcome